Sugi Predict

Sugi Predict / Compounds / SCHEMBL1603150

SCHEMBL1603150

SCHEMBL1603150

Cc1ccc(C)c2c1[nH]c1ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 1.00
▸ MEN1 O00255 4/20 1.00
▸ KMT2A Q03164 4/20 1.00
▸ KIF11 P52732 1/20 0.62
▸ GABRP O00591 4/20 0.51
▸ GABRD O14764 4/20 0.51
▸ GABRA1 P14867 4/20 0.51
▸ GABRB1 P18505 4/20 0.51
▸ GABRG2 P18507 4/20 0.51
▸ GABRB3 P28472 4/20 0.51
▸ GABRA5 P31644 4/20 0.51
▸ GABRA3 P34903 4/20 0.51
▸ GABRA2 P47869 4/20 0.51
▸ GABRB2 P47870 4/20 0.51
▸ GABRA4 P48169 4/20 0.51
▸ GABRE P78334 4/20 0.51
▸ GABRA6 Q16445 4/20 0.51
▸ GABRG1 Q8N1C3 4/20 0.51
▸ GABRG3 Q99928 4/20 0.51
▸ GABRQ Q9UN88 4/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29402096 1.00 MAPT (1.00) MAPTMEN1KMT2AKIF11GABRP
SCHEMBL29150374 0.85 MEN1 (0.73) MAPTMEN1KMT2AKIF11GABRP
SCHEMBL14198729 0.85 MEN1 (0.73) MAPTMEN1KMT2AKIF11GABRP
SCHEMBL29172842 0.82 MAPT (0.69) MAPTMEN1KMT2AKIF11GABRP
SCHEMBL14701113 0.82 MAPT (0.69) MAPTMEN1KMT2AKIF11GABRP
SCHEMBL22389562 0.82 MAPT (0.67) MAPTMEN1KMT2AKIF11GABRP
SCHEMBL11741897 0.79 MAPT (0.65) MAPTMEN1KMT2AKIF11GABRP
SCHEMBL22044984 0.79 MAPT (0.65) MAPTMEN1KMT2AKIF11GABRP
SCHEMBL554573 0.78 MAPT (0.64) MAPTMEN1KMT2AKIF11GABRP
SCHEMBL8573302 0.78 MEN1 (0.63) MAPTMEN1KMT2AKIF11PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114058306-B Underfill adhesive, and preparation method and application thereof 韦尔通科技股份有限公司 2023-07-21 — — CN claimed
CN-114058306-A Underfill adhesive and preparation method and application thereof 韦尔通(厦门)科技股份有限公司 2022-02-18 — — CN claimed
CN-111100123-B A process for preparing ellipticine or substituted ellipticine 中国医学科学院药物研究所 2021-08-13 — — CN claimed
CN-111100123-A Simple method for preparing ellipticine or substituted ellipticine 中国医学科学院药物研究所 2020-05-05 — — CN claimed
US-7919500-B2 Bis-carbazole DNA intercalating agents for antitumor therapy TRUSTEES OF DARTMOUTH COLLEGE (US) 2011-04-05 — — US claimed
EP-0009445-B1 PROCESS FOR THE PREPARATION OF 9-HYDROXY-ELLIPTICINE AND DERIVATIVES THEREOF ANVAR Agence Nationale de Valorisation de la Recherche (FR) 1983-05-18 — — EP claimed
JP-2279671-A — — None — — JP disclosed
CN-114555587-B New carbazole derivatives for sensitizing cells to anticancer agents 国家科学研究中心 2024-07-02 — — CN disclosed
CN-117486782-A N-substituted carbazole derivative and preparation method and application thereof 中国医学科学院药用植物研究所 2024-02-02 — — CN disclosed
CN-116875243-B High-flexibility, impact-resistant and low-temperature quick-curing underfill and preparation method thereof 韦尔通科技股份有限公司 2024-01-23 — — CN disclosed
CN-116875243-A High-flexibility, impact-resistant and low-temperature quick-curing underfill and preparation method thereof 韦尔通科技股份有限公司 2023-10-13 — — CN disclosed
CN-114058306-B Underfill adhesive, and preparation method and application thereof 韦尔通科技股份有限公司 2023-07-21 — — CN disclosed
US-11491711-B2 Method of making 3D printed objects using two distinct light sources PHOTOCENTRIC LIMITED (GB) 2022-11-08 — — US disclosed
US-7919500-B2 Bis-carbazole DNA intercalating agents for antitumor therapy TRUSTEES OF DARTMOUTH COLLEGE (US) 2011-04-05 — — US disclosed
US-20100010033-A1 Bis-carbazole DNA intercalating agents for antitumor therapy TRUSTEES OF DARTMOUTH COLLEGE 2010-01-14 — — US disclosed
US-6551501-B1 Pretreating with a selective adsorbent to remove polar materials HALDOR TOPSOE A/S (DK) 2003-04-22 — — US disclosed
CN-1277988-A Modifying and hydrogenation processing for diesel union method HALDOR TOPSOE AS DE (DK) 2000-12-27 — — CN disclosed
EP-1057879-A2 A combined process for improved hydrotreating of diesel fuels Haldor Topsoe A/S (DK) 2000-12-06 — — EP disclosed
CN-1263092-A Carboxylic compound and its preparation method and application LANZHOU CHEM PHYS INST (CN) 2000-08-16 — — CN disclosed
JP-H02279671-A PRODUCTION OF 1,4-DIMETHYLCARBAZOLE DERIVATIVE SHIRATORI SEIYAKU KK 1990-11-15 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010033-A1 Bis-carbazole DNA intercalating agents for antitumor therapy TOP1, ACIN1, TOP2A MAPT 4425/4885MEN1 3645/4885KMT2A 943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.